By Business/Source
Currency:EUR
2025/FY
Stock NameRevenueRatio
Research and development of PRAME-directed immunotherapies that harness the power of T cells for48.27M100.00%
By Country/Region
Currency:EUR
2025/FY
Stock NameRevenueRatio
Moderna, United States37.25M77.17%
Bristol-Myers-Squibb (BMS) United States11.02M22.83%